Changes to the 340B Program in 2026 – Inflation
Reduction Act and More
April 16, 2026 1:00–2:00 p.m. ET
January 21, 2026 at 1:00 pm (EDT)
Additional Information
Overview
Learning Objectives
Audience
Instructor
Format
Changes to the 340B Program in 2026 – Inflation Reduction Act and More
The federal 340B drug discount program has undergone substantial changes in recent years, with new challenges brought on by manufacturer restrictions and diminishing reimbursement counterbalanced by new opportunities. Perhaps one of the most significant changes are effective on January 1, 2026, when Inflation Reduction Act-mandated negotiated Medicare prices took effect for ten drugs.
This session provides an update on the latest changes to the 340B program, including early experiences with Inflation Reduction Act implementation.
Pharmacy Managers
COOs
CEOs
CFOs
Compliance Officers
Executive Leadership
Understand how Medicare-negotiated pricing will impact 340B program operations and reimbursement
Navigate changes to 340B program compliance
Prepare your organization for the likely evolution of the 340B program.
Jason Reddish
Principal
Jason has focused primarily on the 340B Program for the past 13-plus years, representing community health centers, Ryan White HIV/AIDS clinics, and STD program grantees primarily for the past 8 years. His time is split nearly evenly among transactions, compliance, remedial action, and advocacy for covered entity protections at the state and federal level.
Jason earned a B.S. in Physiology / Neurobiology from the University of Maryland and his J.D. from Tulane University. He is licensed in MD, DC, and Ontario.
This is a 60-minute webinar session.
The session will be recorded.
The recording will be available on-demand shortly after the live session is concluded.
